Log In
Print
BCIQ
Print
Print this Print this
 

Nouriast, istradefylline (KW-6002)

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionAdenosine A2A receptor (ADORA2A) antagonist
Molecular Target Adenosine A2A receptor (ADORA2A)
Mechanism of ActionAdenosine A2 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat idiopathic Parkinson's disease (PD) as adjunctive therapy to levodopa/carbidopa; Treat Parkinson's disease (PD)
Regulatory Designation

U.S. - Special Protocol Assessment (Treat idiopathic Parkinson's disease (PD) as adjunctive therapy to levodopa/carbidopa)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today